Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

Wu, CP ; Zhu, YB ; Jiang, JT ; Zhao, JM ; Zhang, XG and Xu, Ning LU (2006) In Acta Histochemica 108(1). p.19-24
Abstract
The present study examined programmed death-1 ligand-1 (PD-L1) detected by immunohistochemical. labeling in 102 cases of human gastric carcinoma, 10 adenoma and 10 normal tissues. The relationship between PD-L1 immunolocalization and clinical pathological features, as well as the prognosis of gastric carcinoma, was explored. There was no PD-L1 detectable in normal gastric tissues and very weak immunolabeling in gastric adenomas, but it could be detected in 42.2% of gastric carcinoma tissues. There was no correlation between PD-L1 immunolocalization and patient age, sex, tumor location or the degree of tumor differentiation in the gastric carcinomas. However, PD-L1 immunodetection was significantly correlated to tumor size, invasion, lymph... (More)
The present study examined programmed death-1 ligand-1 (PD-L1) detected by immunohistochemical. labeling in 102 cases of human gastric carcinoma, 10 adenoma and 10 normal tissues. The relationship between PD-L1 immunolocalization and clinical pathological features, as well as the prognosis of gastric carcinoma, was explored. There was no PD-L1 detectable in normal gastric tissues and very weak immunolabeling in gastric adenomas, but it could be detected in 42.2% of gastric carcinoma tissues. There was no correlation between PD-L1 immunolocalization and patient age, sex, tumor location or the degree of tumor differentiation in the gastric carcinomas. However, PD-L1 immunodetection was significantly correlated to tumor size, invasion, lymph node metastasis and survival time of patients. PD-L1 immunolabeling was significantly enhanced (P<0.01) when the tumor infiltrated into the deep muscular layers, with lymph node metastasis or survival time of less than 2 years, Moreover, multivariate analysis demonstrated that PD-L1 immunodetection could be used as an independent factor to evaluate the prognosis of gastric carcinoma. (C) 2006 Elsevier GmbH. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
gastric carcinoma, programmed death-1 ligand-1, PD-L1, prognostic marker, immunohistochemistry
in
Acta Histochemica
volume
108
issue
1
pages
19 - 24
publisher
Elsevier
external identifiers
  • pmid:16530813
  • wos:000237919500003
  • scopus:33745491116
  • pmid:16530813
ISSN
0065-1281
DOI
10.1016/j.acthis.2006.01.003
language
English
LU publication?
yes
id
e024e4aa-b9e3-46fb-afcf-f4480e98352b (old id 408463)
date added to LUP
2016-04-01 11:46:14
date last changed
2020-12-27 05:08:08
@article{e024e4aa-b9e3-46fb-afcf-f4480e98352b,
  abstract     = {The present study examined programmed death-1 ligand-1 (PD-L1) detected by immunohistochemical. labeling in 102 cases of human gastric carcinoma, 10 adenoma and 10 normal tissues. The relationship between PD-L1 immunolocalization and clinical pathological features, as well as the prognosis of gastric carcinoma, was explored. There was no PD-L1 detectable in normal gastric tissues and very weak immunolabeling in gastric adenomas, but it could be detected in 42.2% of gastric carcinoma tissues. There was no correlation between PD-L1 immunolocalization and patient age, sex, tumor location or the degree of tumor differentiation in the gastric carcinomas. However, PD-L1 immunodetection was significantly correlated to tumor size, invasion, lymph node metastasis and survival time of patients. PD-L1 immunolabeling was significantly enhanced (P&lt;0.01) when the tumor infiltrated into the deep muscular layers, with lymph node metastasis or survival time of less than 2 years, Moreover, multivariate analysis demonstrated that PD-L1 immunodetection could be used as an independent factor to evaluate the prognosis of gastric carcinoma. (C) 2006 Elsevier GmbH. All rights reserved.},
  author       = {Wu, CP and Zhu, YB and Jiang, JT and Zhao, JM and Zhang, XG and Xu, Ning},
  issn         = {0065-1281},
  language     = {eng},
  number       = {1},
  pages        = {19--24},
  publisher    = {Elsevier},
  series       = {Acta Histochemica},
  title        = {Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance},
  url          = {http://dx.doi.org/10.1016/j.acthis.2006.01.003},
  doi          = {10.1016/j.acthis.2006.01.003},
  volume       = {108},
  year         = {2006},
}